MAPS just released huge news regarding their phase 3 trial readouts on PTSD, just published in Nature Medicine. This phase 3 trial was intended to evaluate the efficacy and safety of MDMA assisted therapy (MDMA-AT) for participants with moderate to severe PTSD. Joining us for this Trade To Black podcast is Numinus Wellness (TSX: NUMI) CEO Payton Nyquvest.
These groundbreaking findings from the MAPP2 Trial confirmed that MDMA-AT is indeed effective for treating PTSD. Participants treated with MDMA experienced a significant reduction in symptoms of PTSD compared to the participants in the control group who had been given only a placebo. The results appear to indicate that approximately 86% of participants treated with MDMA-AT achieved “a clinically meaningful benefit” and 71.2% of participants no longer met the criteria for PTSD by the end of the study. The improvements were seen in different aspects of their lives, such as family, social interactions, and work.
This study supports the findings from a previous trial and brings hope for a new psychedelic treatment option for people with PTSD. The trial included individuals with moderate or severe PTSD and followed a strict research design.
The study also looked at the safety of MDMA-AT. The reported side effects were similar to what has been observed in previous studies, and there were no major concerns. No cases of MDMA abuse or dependence were reported. Some participants experienced temporary increases in blood pressure and heart rate during therapy sessions, but these changes did not require medical intervention.
Join us as we explore and talk about this transformative approach to mental health treatment. Nyquvest says that now is the time to begin investing in training practitioners and building a clinical infrastructure. Numinus has begun modeling profitability and has expectations and projections. Where does PTSD go from here now that MAPS has released the readouts? Find out when you tune into the podcast!
